CLARION MULTI-STRATEGY COCHLEAR IMPLANT
Advanced Bionics · Decision date Sep 18, 2026
What did the FDA approve?
The FDA record lists P960058/S178 for Advanced Bionics as an approval dated 2026-09-18 on the normal 180-day track without a user fee, classified as a postapproval study protocol supplement under product code MCM. The changed item is the postapproval study (PAS) protocol itself, not the cochlear implant system's original approval. The record gives no protocol content, study design, endpoints, sample size, or timeline.
The listed statement says this PAS protocol was submitted to comply with conditions of approval in the approval order for P960058/S167. That reports the sponsor's stated purpose relative to a prior supplement; it is not independent proof of safety or clinical effectiveness, and the record does not describe S167's conditions. The descriptor 'Normal 180 Day Track No User Fee' is the review pathway and fee status, not a new device approval.
FDA approval order statement
The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P960058/S167.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Ear, Nose, Throat
- Decision date
- Sep 18, 2026
- FDA change category
- Postapproval Study Protocol
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P960058/S178
- Regulatory pathway
- PMA supplement
- Applicant
- Advanced Bionics
- Product code
- MCM
- Decision code
- APPR
- Decision date
- Sep 18, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, cochlear.
- Applicant
- Advanced Bionics
- Product code
- MCM
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P960058. Subsequent supplements may change the device or its indications.
FDA decision timeline
P960058 · Original PMA
CLARION MULTI-STRATEGY COCHLEAR IMPLANT
P960058/S178 received
Application receipt date recorded by FDA.
P960058/S177 · Related supplement
HiResolution Bionic Ear System
P960058/S178 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P960058. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P960058
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Advanced Bionics | PMA approval | Jun 26, 1997 | FDA | |
HiResolution Bionic Ear SystemP960058/S177 | Advanced Bionics | PMA supplement | Sep 4, 2026 | FDA |
Explore the linked device profile
Other records with product code MCM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
MED-EL Cochlear Implant SystemP000025/S136 | Med-El Corp. | PMA supplement | Oct 9, 2026 | FDA |
Nucleus 22 Cochlear Implant SystemP840024/S099 | Cochlear Americas | PMA supplement | Sep 28, 2026 | FDA |
Nucleus 22 Cochlear Implant SystemP890027/S067 | Cochlear Americas | PMA supplement | Sep 28, 2026 | FDA |
Nucleus 24 Cochlear Implant SystemP970051/S244 | Cochlear Americas | PMA supplement | Sep 28, 2026 | FDA |
| Med-El Corp. | PMA approval | Aug 20, 2001 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Advanced Bionics
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 28515 Westinghouse Pl., Valencia, CA, 91355
Sources and methodology
- Original FDA record: P960058/S178
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




